Related Experiment Video
Updated: Jun 30, 2025
07:02
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
6.3K
Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy
J Chase Cole1, Samantha F Benvie2, Marci DeLosSantos1
1Department of Pharmacy, University of Florida Health-Jacksonville, Jacksonville, Florida.
Clinical Therapeutics
|March 20, 2024
Summary
Mavacamten offers a new, targeted treatment for hypertrophic cardiomyopathy (HCM), improving symptoms and exercise capacity in patients with obstructive HCM. This novel therapy may reduce the need for invasive procedures.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease causing significant morbidity and mortality.
- Previous treatments for HCM were not disease-specific and often poorly tolerated.
- Limited therapeutic options existed for patients with persistent HCM symptoms.
Purpose of the Study:
- To review the pharmacology of mavacamten, a novel drug for hypertrophic cardiomyopathy.
- To discuss clinical trials supporting the use of mavacamten in HCM management.
- To outline considerations for the clinical application of mavacamten.
Main Methods:
- Literature search of PubMed and ClinicalTrials.gov for mavacamten and Camzyos (January 2015-March 2023).
- Inclusion of data from key clinical trials: EXPLORER-HCM and VALOR-HCM.
- Exclusion of non-randomized, controlled trials.
Main Results:
- Mavacamten demonstrated efficacy in treating symptomatic obstructive HCM.
- Treatment with mavacamten improved exercise capacity and New York Heart Association functional class.
- Mavacamten use was associated with reduced left ventricular outflow tract obstruction and decreased need for septal reduction therapy.
Conclusions:
- Mavacamten represents a novel therapeutic option for patients with HCM.
- It offers improved outcomes for those with persistent symptoms and obstructive HCM.
- Future trials may expand mavacamten's indication to nonobstructive HCM.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338